Table 1 Patients' features
KRASwild-type, no. (%) | KRASmutant, no. (%) | Total no. (%) | |
|---|---|---|---|
No. of patients | 31 (53) | 28 (47) | 59 |
Male/female | 21/10 | 16/12 | 37/22 |
Age, years: | |||
Median | 64 | 65 | 63 |
Range | 42 to 73 | 48 to 73 | 42 to 73 |
≥65 | 13 (42) | 13 (46) | 26 (44) |
WHO performance status: | |||
0 | 28 (90) | 26 (93) | 54 (92) |
1 to 2 | 3 (10) | 2 (7) | 5 (8) |
Metastatic disease: | |||
Metachronous | 10 (32) | 7 (25) | 17 (29) |
Synchronous | 21 (68) | 21 (75) | 42 (71) |
Primary tumor: | |||
Colon | 14 (45) | 20 (71) | 34 (58) |
Rectum | 17 (55) | 8 (29) | 25 (42) |
Sites of metastases: | |||
Liver | 19 (61) | 20 (71) | 39 (66) |
Lung | 7 (23) | 5 (18) | 12 (20) |
Lymph nodes | 10 (32) | 8 (29) | 18 (30) |
Local | 6 (19) | 3 (11) | 9 (15) |
Other | 2 (6) | 6 (21) | 8 (14) |
No. of involved sites: | |||
1 | 17 (55) | 17 (61) | 34 (58) |
≥2 | 14 (45) | 11 (39) | 25 (42) |
Single metastatic sites: | |||
Liver limited | 12 (39) | 13 (46) | 25 (42) |
Other than liver | 7 (22) | 4 (15) | 11 (19) |
Lung | 2 (6) | 2 (7) | 4 (7) |
Lymph nodes | 2 (6) | 1 (4) | 3 (5) |
Local | 3 (10) | 1 (4) | 4 (7) |
Multiple metastatic sites | 12 (39) | 11 (39) | 23 (39) |
Liver metastases: | |||
Single | 8 (26) | 3 (11) | 11 (19) |
Multiple | 11 (35) | 11 (39) | 22 (37) |
Previous adjuvant chemotherapy: | 6 (19) | 2 (7) | 8 (14) |
FA/5-FU bolus | 3 (10) | - | 3 (5) |
Capecitabine | - | - | - |
FOLFOX4 | 2 (6) | 2 (7) | 4 (7) |
XelOx | 1 (3) | - | 1 (2) |
Previous radiotherapy: | 4 (13) | 1 (4) | 5 (8) |
Radiotherapy alone | - | - | - |
Radiotherapy + chemotherapy (5-FU continuous infusion) | 2 (6) | - | 2 (3) |
Radiotherapy + chemotherapy (XELOX) | 2 (6) | 1 (4) | 3 (5) |